Sign in to continue:

Thursday, April 16th, 2026

天津渤海化学2025年度拟不进行利润分配公告:未分配利润为负数,股东需审议决议

渤海化学2025年度利润分配预案公告详解

渤海化学2025年度利润分配预案公告详解

关键信息摘要

  • 公司名称:天津渤海化学股份有限公司
  • 公告内容:2025年度公司拟不进行利润分配,既不派发现金红利、不送红股,也不以资本公积转增股本。
  • 主要原因:2025年末合并报表及母公司财务报表累计未分配利润为负数。
  • 净利润情况:2025年度归属于母公司所有者的净利润为-6.46亿元,年初未分配利润为-16.31亿元,期末未分配利润为-22.77亿元。
  • 相关会议:利润分配预案已获董事会及审计委员会通过,待提交股东大会审议。
  • 风险事项:公司未触及上交所股票上市规则中关于实施其他风险警示的情形。

公告详情解读

天津渤海化学股份有限公司(证券代码:600800)于2026年4月17日发布公告,明确表示因公司2025年度盈利状况恶化,累计未分配利润持续为负,公司董事会决定2025年度不进行任何形式的利润分配,包括不派发现金红利、不送红股,也不以资本公积金转增股本。

财务数据情况:根据大信会计师事务所出具的2025年度财务审计报告,渤海化学2025年归属于母公司所有者的净利润为-646,342,302.81元,2025年年初未分配利润为-1,630,535,951.14元,期末未分配利润为-2,276,878,253.95元。这表明公司经营状况较为严峻,亏损持续扩大。

分红条件不满足说明:根据中国证监会《上市公司监管指引第3号——上市公司现金分红》及《公司章程》相关规定,公司实施现金分配须满足:可分配利润为正值、累计可供分配利润为正值、审计报告为无保留意见等条件。由于公司2025年末累计未分配利润为负,且净利润为负值,因此不具备分红的基本条件。

决策流程:本次利润分配预案已于2026年4月13日通过第十届董事会审计委员会第二十次会议审议,4月16日经第十届董事会第二十三次会议全体董事一致同意通过,现提交公司股东大会进一步审议。

风险提示:公司明确表示,当前情况并未触及《上海证券交易所股票上市规则》第9.8.1条关于可能被实施其他风险警示的情形。

对股东及投资者的影响

  • 分红预期落空:公司连续亏损且未分配利润为负,2025年度不进行任何利润分配,可能对投资者的分红预期造成影响。
  • 公司经营压力:巨额亏损及持续亏损状态,反映公司目前经营压力较大,长期盈利能力需投资者高度关注。
  • 股价可能波动:利润分配预案对公司现金流状况及再投资能力有一定保护作用,但消息披露后或将对公司短期股价产生不利影响。
  • 风险提示:本预案尚需股东大会审议通过,投资者需注意相关不确定性,理性投资。

结论

渤海化学2025年度因持续亏损并导致未分配利润为负,公司决定不进行任何利润分配。此次公告对投资者的分红预期和公司经营状况均有较大影响,建议投资者持续关注公司后续治理及经营改善情况,合理评估投资风险。


免责声明:本文仅供投资者参考,不构成任何投资建议。投资有风险,入市需谨慎。请以公司公告及相关会议最终决议为准。

Bohai Chemical 2025 Profit Distribution Plan Detailed Report

Key Highlights

  • Company: Tianjin Bohai Chemical Co., Ltd.
  • Announcement: The company will not distribute profits for 2025 — no cash dividends, no bonus shares, and no transfer of capital reserve to share capital.
  • Main Reason: The company’s cumulative undistributed profits at year-end 2025 remain negative.
  • Net Profit Situation: Net loss attributable to shareholders for 2025 is RMB -646 million; beginning undistributed profits was RMB -1,630 million, ending at RMB -2,276 million.
  • Related Meetings: The profit distribution plan was approved by the Board and Audit Committee and is pending shareholder approval.
  • Risk Matters: The company does not trigger any additional risk warnings as per the Shanghai Stock Exchange Listing Rules.

Detailed Announcement Analysis

Tianjin Bohai Chemical Co., Ltd. (stock code: 600800) announced on April 17, 2026, that due to continued poor performance and negative undistributed profits for 2025, the Board has resolved not to distribute profits for the year. This means no cash dividends, bonus shares, or capital reserve conversions will be made.

Financial Data: The 2025 audit by DaXin CPA firm shows a net loss of RMB -646,342,302.81, with undistributed profits starting at RMB -1,630,535,951.14 and ending at RMB -2,276,878,253.95. The company’s operating condition is severe, with losses expanding.

Unmet Dividend Conditions: According to CSRC and company charter requirements, profit distribution requires positive distributable profit, positive cumulative distributable profit, and an unqualified audit report. The company fails these prerequisites due to negative profits.

Decision Process: The plan was approved by the Audit Committee on April 13, 2026, and unanimously passed by the Board on April 16, 2026. It is now pending a shareholder meeting vote.

Risk Warning: The company confirms that its current situation does not meet the Shanghai Stock Exchange’s criteria for other risk alerts.

Impact on Shareholders and Investors

  • Missed Dividend Expectations: Continued losses and negative undistributed profits mean no profit distribution for 2025, which may disappoint investors expecting dividends.
  • Operational Pressure: The ongoing and significant losses signal strong operational challenges, which should be closely monitored by investors.
  • Potential Share Price Volatility: While the plan helps preserve company cash flow, the news may negatively impact the stock price in the short term.
  • Risk Reminder: The plan is subject to shareholder approval; investors should remain alert to uncertainties and invest rationally.

Conclusion

Bohai Chemical’s decision not to distribute profits in 2025 due to continued losses significantly affects investor expectations and reflects the company’s challenging business environment. Investors are advised to closely follow the company’s future governance and recovery efforts and assess risks prudently.


Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investing carries risks; please refer to official company disclosures and final meeting resolutions for authoritative information.


View 渤海化学 Historical chart here



Zhejiang Pharmaceutical (600216) Major Shareholder Announces Up to 1% Share Reduction Plan via Centralized Bidding

浙江医药股份有限公司大股东减持公告深度解读 浙江医药股份有限公司大股东减持计划公告深度解读 一、公告要点概述 大股...

中航直升机股份有限公司发行股份购买资产并募集配套资金暨关联交易2025年度持续督导总结报告

中航直升机2025年度重大资产重组持续督导总结详解 中航直升机股份有限公司2025年度重大资产重组持续督导总结详解...

Hunan Huasheng Co., Ltd. 2025 Annual Report Summary: Industry Trends, Business Overview, Financial Data, and Shareholder Information

湖南华升股份有限公司2025年年度报告摘要深度解读:行业承压转型,业绩改善但仍亏损,投资者需重点关注 湖南华升股份有...

   Ad